title: Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
authors: Silvio
authors: S
authors: Danese
authors: Filippo
authors: F
authors: Mocciaro
authors: Luisa
authors: L
authors: Guidi
authors: Maria Lia
authors: ML
authors: Scribano
authors: Michele
authors: M
authors: Comberlato
authors: Vito
authors: V
authors: Annese
authors: Elisabetta
authors: E
authors: Colombo
authors: Tommaso
authors: T
authors: Stefanelli
authors: Manuela
authors: M
authors: Marzo
authors: Marcello
authors: M
authors: Vangeli
authors: Raffaella
authors: R
authors: Pulitano'
authors: Aldo
authors: A
authors: Manca
authors: Alessandro
authors: A
authors: Armuzzi
authors: Alberto
authors: A
authors: Malesci
authors: Cosimo
authors: C
authors: Prantera
authors: Mario
authors: M
authors: Cottone
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D066298:In Vitro Techniques; D000069285:Infliximab; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068582:Certolizumab Pegol